Announcement: The upgraded high-potency human diploid rabies vaccine has completed Phase III clinical fieldwork

AIM VACCINE wrote a column · Jan 14 19:30

This announcement is voluntarily made by Aim Vaccine Co., Ltd. ("the Company," together with its subsidiaries, referred to as "the Group") to inform the shareholders and potential investors of the latest business developments within the Group.

The upgraded high-potency human diploid rabies vaccine developed by our Group has successfully completed its Phase III clinical fieldwork. This marks the official entry of the vaccine into a new stage, laying a solid foundation for future commercialization and market launch.

This product is an iterated and upgraded human diploid rabies vaccine with the distinct feature of ultra-high potency, representing a significant iteration upgrade in the global rabies vaccine technology field. Animal studies have shown that after immunization, our Group's human diploid rabies vaccine can generate antibodies at a high protective level. Under the same dosage conditions, the potency of our Group’s human diploid rabies vaccine is significantly higher than that of currently marketed human diploid rabies vaccines.

Rabies is the disease with the highest mortality rate in the world, with a near 100% fatality rate once symptoms appear. Currently, there is no effective clinical treatment for rabies, making post-exposure prevention crucial, primarily through the administration of human rabies vaccines. Compared to traditional Vero cell rabies vaccines, human diploid cell rabies vaccines use human diploid cells instead of Vero cells. These cells are homologous to humans, providing a natural safety advantage. Currently, human diploid cell rabies vaccines on the market are priced 3 to 5 times higher than Vero cell rabies vaccines, offering greater product added value.

Compared to traditional first-generation human diploid rabies vaccines, the high-potency human diploid rabies vaccine developed by our group using an iterative process has pioneered breakthroughs in the technical bottlenecks of low virus titer and low yield inherent in traditional processes. It has also introduced optimized innovations in purification techniques, significantly improving both product quality and safety. This achievement not only demonstrates the company’s R&D capabilities but also represents a major advancement in the field of high-potency rabies vaccine technology globally.

China is the largest market for rabies vaccines globally. According to data from灼识咨询 (CIC), driven by product upgrades and increased awareness of rabies vaccines, the market is expected to reach 14.8 billion yuan by 2030. Compared to traditional rabies vaccine dosing regimens, the product developed by our group offers flexible vaccination options, including the 'five-dose method,' 'simplified four-dose method,' and the '2-1-1 four-dose method,' which are more convenient. Per the guidelines outlined in the 《National Rabies Prevention and Control Guidelines (2023 Edition)》issued by the National Disease Control Administration and the National Health Commission, rabies vaccination clinics must stock at least two types of rabies vaccines. Our group's product, with its advanced technological iteration and flexible vaccination options, is well-positioned to become the preferred choice for vaccination facilities. Our group has constructed a fully compliant, international-standard production facility for high-potency human diploid rabies vaccines using the iterative process and has completed the production of commercial-scale Phase III clinical trial samples, demonstrating the capability for large-scale manufacturing.

The human diploid cell rabies vaccine is recommended by the WHO as the gold standard for rabies vaccines and has been widely used in many developed countries. As the second-largest global supplier of rabies vaccines, Aim Vaccine is committed to leading the deep technological iteration and upgrading of rabies vaccines worldwide, delivering a series of higher-quality and safer rabies vaccine products to the market. This further solidifies the company's leading position in the global rabies vaccine sector and promotes sustainable development. The approval of this product in the future will further diversify the company's product portfolio, creating synergies with its existing rabies vaccine series and enhancing core competitiveness. As part of the globalization strategy, it can contribute additional revenue streams, strengthen the company’s market position, and add new momentum for continued stable growth.

Risk Disclaimer: The above content only represents the author's view. It does not represent any position or investment advice of Futu. Futu makes no representation or warranty. Read more

See Original

Report

29K Views

Comment

AIM VACCINE

The official account of AIM Vaccine Co Ltd

16K

Followers

17K

Visitors

No. Symbol % Chg

Tariff game between the US and Europe shakes the market! Will TACO happen again?

Amidst the global market turbulence triggered by the US-Europe dispute over Greenland, a single post by Trump instantly reversed market tren Show More

Futubull Options Sir

Jan 19 17:47

Options Weekly 0119 | Greenland tariff standoff, gold and silver surge again, shocking reversal in Fed chair nominee! Watch Intel, Netflix earnings reports

年頭旺到年尾

Jan 25 15:05

2026 Futu Creators Conference